viewAvacta Group PLC

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half.

Stacey says alongside the recent release of their interim results, Avacta's announced a proposed equity placing of up to £9mln.

The biggest deployment of the new funds will be the AVA6000 pro-doxorubicin tumour-targeted chemotherapy programme developed via the Tufts collaboration.

Quick facts: Avacta Group PLC

Price: 17.94 GBX

Market: AIM
Market Cap: £31.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...



Full interview: Avacta Group PLC boss sees a huge opportunity with new...

Alastair Smith, Avacta Group PLC’s (LON:AVCT) chief executive, believes it has huge opportunities for a new version of cancer treatment Doxorubicin using the technology it licensed from Tufts University. Doxorubicin has been a standard treatment for soft tissue cancers for decades, but heart...

on 21/10/19

2 min read